CN107427464B - 眼用悬浮液组合物 - Google Patents

眼用悬浮液组合物 Download PDF

Info

Publication number
CN107427464B
CN107427464B CN201680016825.XA CN201680016825A CN107427464B CN 107427464 B CN107427464 B CN 107427464B CN 201680016825 A CN201680016825 A CN 201680016825A CN 107427464 B CN107427464 B CN 107427464B
Authority
CN
China
Prior art keywords
ophthalmic
suspension
formulation
particles
ophthalmic suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680016825.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107427464A (zh
Inventor
M·沙维尔
E·菲利普斯
M·J·科菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55359733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107427464(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of CN107427464A publication Critical patent/CN107427464A/zh
Application granted granted Critical
Publication of CN107427464B publication Critical patent/CN107427464B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680016825.XA 2015-01-26 2016-01-26 眼用悬浮液组合物 Active CN107427464B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562107696P 2015-01-26 2015-01-26
US62/107,696 2015-01-26
PCT/US2016/014872 WO2016123079A1 (en) 2015-01-26 2016-01-26 Ophthalmic suspension composition

Publications (2)

Publication Number Publication Date
CN107427464A CN107427464A (zh) 2017-12-01
CN107427464B true CN107427464B (zh) 2022-04-05

Family

ID=55359733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680016825.XA Active CN107427464B (zh) 2015-01-26 2016-01-26 眼用悬浮液组合物

Country Status (15)

Country Link
US (3) US10596107B2 (cg-RX-API-DMAC10.html)
EP (5) EP3250185B1 (cg-RX-API-DMAC10.html)
JP (1) JP2018507252A (cg-RX-API-DMAC10.html)
KR (1) KR102538370B1 (cg-RX-API-DMAC10.html)
CN (1) CN107427464B (cg-RX-API-DMAC10.html)
AU (4) AU2016211745A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017016016B1 (cg-RX-API-DMAC10.html)
CA (1) CA2975106A1 (cg-RX-API-DMAC10.html)
ES (5) ES2966595T3 (cg-RX-API-DMAC10.html)
HU (5) HUE048564T2 (cg-RX-API-DMAC10.html)
MX (1) MX390671B (cg-RX-API-DMAC10.html)
PL (5) PL3470059T3 (cg-RX-API-DMAC10.html)
PT (3) PT4082531T (cg-RX-API-DMAC10.html)
SI (1) SI4268850T1 (cg-RX-API-DMAC10.html)
WO (1) WO2016123079A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048564T2 (hu) 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
US11000475B2 (en) 2015-10-16 2021-05-11 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
LT3245988T (lt) 2016-05-18 2024-02-12 Sonikure Holdings Limited Ultragarsu pagerinto transsklerinio vaistų pristatymo sistema
CA3073195A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
CA3112278A1 (en) * 2018-09-21 2020-03-26 Ps Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JP2022520410A (ja) * 2019-02-15 2022-03-30 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの結晶形態及びその製剤
CA3148362C (en) * 2019-08-18 2024-02-13 Bo Liang In-situ gel forming ophthalmic formulations containing difluprednate
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
FR3170261A1 (fr) 2024-12-23 2026-06-26 Horus Pharma Composition ophtalmique sous forme de gel comprenant du polycarbophile

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
IE63392B1 (en) 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2134376C (en) 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
AU684115B2 (en) * 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
GB9718568D0 (en) * 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
CA2839849C (en) 2003-06-13 2017-03-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20100234336A1 (en) 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20120028947A1 (en) 2005-11-14 2012-02-02 Erning Xia Ophthalmic Compositions
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
CN101966143A (zh) 2009-07-28 2011-02-09 胡容峰 加替沙星温度及pH敏感眼用凝胶的制备与应用
HUE038821T2 (hu) 2009-12-03 2018-11-28 Novartis Ag Karboxivinil polimert tartalmazó nanorészecske szuszpenziók
CA2851492A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
CN111700878A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
JP6054380B2 (ja) 2012-05-11 2016-12-27 株式会社アクティバスファーマ 有機化合物ナノ粉体、その製造方法ならびに懸濁液
WO2013169458A1 (en) 2012-05-11 2013-11-14 Bausch & Lomb Incorporated Pharmaceutical compositions and methods for treating, controlling, ameliorating, or reversing conditions of dry eye
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
US20150190407A1 (en) 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
AU2015288643B2 (en) 2014-07-11 2017-12-14 Fujifilm Corporation Method for producing aqueous ophthalmic composition, and aqueous ophthalmic composition
AU2015288644B2 (en) 2014-07-11 2017-12-14 Fujifilm Corporation Aqueous ophthalmic composition
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
HUE048564T2 (hu) 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A Screening Study of Surface Stabilization during the roduction of Drug Nanocrystals;BERNARD VAN EERDENBRUGH，等;《PHARMACEUTICAL NANOTECHNOLOGY》;20090630;第98卷(第6期);第2092页左栏最后1段以及第2093页Fig.1，第2092-2100页 *
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop;Martin J Coffey，等;《Clinical Ophthalmology》;20130213;第7卷;第303页左栏最后1段、右栏最后1段以及第302页表2 *
In-Situ Gelling System: A Novel Approach for Ocular Drug Delivery;Rajoria，等;《Am. J. PharmTech Res.》;20121231;第2卷(第4期);第37页第2段 *
Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation;Lisa Schopf，等;《Ophthalmology and Therapy》;20140204;第3卷;第65页左栏第2段以及第66-69页Fig.1-3以及表1 *
Therapeutic Effects of Gel Ointments Containing Tranilast Nanoparticles;Noriaki，等;《Biol. Pharm. Bull.》;20140101;第37卷(第1期);第97页右栏第3段和表1 *

Also Published As

Publication number Publication date
CA2975106A1 (en) 2016-08-04
EP3470059B1 (en) 2020-04-01
AU2021203027A1 (en) 2021-06-10
PL3721868T5 (pl) 2025-12-22
JP2018507252A (ja) 2018-03-15
CN107427464A (zh) 2017-12-01
PL4082531T3 (pl) 2024-04-08
EP3470059A1 (en) 2019-04-17
AU2021203027B2 (en) 2023-07-13
EP4268850B1 (en) 2025-04-16
SI4268850T1 (sl) 2025-07-31
ES2924645T3 (es) 2022-10-10
PT4268850T (pt) 2025-06-04
EP3250185B1 (en) 2018-12-05
BR112017016016B1 (pt) 2023-12-19
US20230140895A1 (en) 2023-05-11
EP4082531B1 (en) 2023-10-11
EP4082531A1 (en) 2022-11-02
PL3250185T3 (pl) 2019-05-31
BR112017016016A2 (pt) 2018-03-20
PT3721868T (pt) 2022-08-12
EP3470059B2 (en) 2026-08-12
ES2787039T3 (es) 2020-10-14
HUE066045T2 (hu) 2024-07-28
AU2023248145A1 (en) 2023-11-02
PL3721868T3 (pl) 2022-11-07
ES2966595T3 (es) 2024-04-23
EP3721868B1 (en) 2022-06-01
EP3721868A1 (en) 2020-10-14
PL3470059T3 (pl) 2020-11-30
US20160213609A1 (en) 2016-07-28
US12589069B2 (en) 2026-03-31
US10596107B2 (en) 2020-03-24
WO2016123079A1 (en) 2016-08-04
PL4268850T3 (pl) 2025-08-04
US11534395B2 (en) 2022-12-27
HUE041945T2 (hu) 2019-06-28
US20200214977A1 (en) 2020-07-09
HUE059639T2 (hu) 2022-12-28
EP3250185A1 (en) 2017-12-06
PT4082531T (pt) 2023-12-14
EP4268850A1 (en) 2023-11-01
ES2704125T3 (es) 2019-03-14
KR102538370B1 (ko) 2023-06-01
HUE048564T2 (hu) 2020-08-28
AU2016211745A1 (en) 2017-08-31
ES3031414T3 (en) 2025-07-08
ES2924645T5 (en) 2025-12-15
HUE071679T2 (hu) 2025-09-28
EP3721868B2 (en) 2025-09-03
MX390671B (es) 2025-03-21
AU2023248145B2 (en) 2025-08-28
KR20170105610A (ko) 2017-09-19
AU2025271194A1 (en) 2025-12-18
MX2017009699A (es) 2017-10-23

Similar Documents

Publication Publication Date Title
US12589069B2 (en) Ophthalmic suspension composition
JP2013522312A (ja) セチリジンの眼用製剤、および使用方法
KR20140069210A (ko) 안과적 겔 조성물
HK40101668A (en) Ophthalmic suspension composition
HK40101668B (en) Ophthalmic suspension composition
HK40082997B (en) Ophthalmic suspension composition
HK40082997A (en) Ophthalmic suspension composition
HK40037317B (en) Ophthalmic suspension composition
HK40037317A (en) Ophthalmic suspension composition
EP4255440A1 (en) Difluprednate for reducing the adverse effects of ocular inflammation
US20130079315A1 (en) Ophthalmic Gel Compositions
US20230364012A1 (en) Stable ophthalmic composition of loteprednol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant